A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

NCT07659795 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: VS-7375
DRUG: cetuximab
DRUG: panitumumab
DRUG: Cetuximab + mFOLFOX6

Sponsor

Verastem, Inc.